Your browser doesn't support javascript.
loading
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.
Huang, Hao; Peng, Ling; Zhang, Bicheng; Till, Brian G; Yang, Yonghao; Zhang, Xiaojie; Zhao, Lingdi; Fu, Xiaomin; Li, Tiepeng; Han, Lu; Qin, Peng; Chen, Lin; Yan, Xiang; Liu, Yang; Wang, Wenkang; Ye, Zhenlong; Li, Hongle; Gao, Quanli; Wang, Zibing.
Afiliação
  • Huang H; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Peng L; Department of Respiratory Disease, Zhejiang Provincial People's Hospital, Hangzhou, China.
  • Zhang B; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
  • Till BG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
  • Yang Y; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Zhang X; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Zhao L; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Fu X; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Li T; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Han L; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Qin P; Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Chen L; Guangzhou Medical University-Guangzhou Institute of Biomedicine and Health GZMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China.
  • Yan X; Medical Oncology Department, Chinese People's Liberation Army PLA General Hospital, Beijing, China.
  • Liu Y; Department of Radiotherapy, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Wang W; Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ye Z; Mengchao Cancer Hospital, Shanghai University, Shanghai, China.
  • Li H; Department of Immune Cell Research, Shanghai Engineering Research Center for Cell Therapy, Shanghai, China.
  • Gao Q; School of Pharmacy, Binzhou Medical University, Binzhou, China.
  • Wang Z; Molecular Pathology Department, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Front Immunol ; 13: 882172, 2022.
Article em En | MEDLINE | ID: mdl-35911715
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China